期刊文献+

达英-35联合二甲双胍治疗多囊卵巢综合征后促排卵效果分析 被引量:10

Analysis of Ovulation Induction Effect of Treating PCOS with Diane-35 Combined Metformin
下载PDF
导出
摘要 目的:探讨达英-35联合二甲双胍对多囊卵巢综合征以及促排卵效果的影响。方法 :67例多囊卵巢综合征患者随机分为对照组和观察组,对照组33例单独应用达英-35治疗,观察组34例给予达英-35联合二甲双胍治疗。结果:治疗后体重和体重指数均有下降,观察组下降更为明显,组间比较具有统计学意义(P<0.05)。治疗后T、LH激素水平较治疗前均有明显降低,组内比较差异具有统计学意义(P<0.05)。FSH、PRL以及E2治疗前后以及治疗后组间比较均无统计学意义(P>0.05),观察组妊娠率显著高于对照组。结论:达英-35联合二甲双胍治疗多卵巢综合征具有显著疗效,能够有效改善患者内分泌失调症状,提高促排卵效果,提高患者妊娠率。 Objective: To explore ovulation induction effect of treating PCOS with Diane-35 combined metformin. Methods: 67 cases of patients with p01ycystic ovary syndrome were randomly divided into control group and observation group, control group 33 cases treated with Diane-35, observation group of 34 cases treated with Diane-35 combined metformin. Results: After treatment there is a decrease in the weight and body mass index, the observation group decreased more significantly than the control group, with statistical significance (P〈0.05). T, LH hormone levels after treatment decreased significantly than that before treat- ment (P〈0.05). FSH, PRL, Ez before and after the treatment had no statistical significance (P〈0.05). The pregnancy rate of observation group is significantly higher than that of the control group. Conclusion:Diane-35 combined metformin has significant curative effect in treating PCOS.
作者 李宇称 彭琦琳 彭惠文 Li Yuchen et al(Huangpi District Maternal and Child Health Care Hospital, Wuhan 43220)
出处 《数理医药学杂志》 2016年第11期1669-1670,共2页 Journal of Mathematical Medicine
关键词 达英-35 二甲双胍 多卵巢综合征 促排卵 Diane-35 metformin ovary syndrome ovulation induction
  • 相关文献

参考文献4

二级参考文献23

  • 1吕述彦,吕述军.二甲双胍对非肥胖 非胰岛素抵抗多囊卵巢综合征的治疗作用[J].中国妇幼保健,2006,21(10):1426-1427. 被引量:4
  • 2刘锦霞,党洁明,吴元赭,郑宁,吴效科.二甲双胍联合环丙孕酮/炔雌醇治疗多囊卵巢综合征的临床研究[J].医学研究生学报,2006,19(6):530-533. 被引量:30
  • 3Diamanti - Kandarakis E, Christakou C. Prevalence, denition and clinical manifestations of polycystic ovary syndrome [ J ]. Endocrinol Nutr,2006,53(Suppl 1) :25 - 33.
  • 4Rautio K,Tapanainen JS, Ruokonen A, et al. Effects of mefformin and ethinyl estradiol- cyproterone acetate on lipid levels in obese and non -obese women with polycystic ovary syndrome[ J]. Eur J Endocrinol,2005,152 (2) :269 - 275.
  • 5Wu J,Zhu Y, Jiang Y, et al. Effects of metformin and ethinyl estradiol - cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystie ovary syndrome [ J ]. Gynecol Endocrinol, 2008,24(7) :392 -398.
  • 6Mitkov M, Pehlivanov B ,Terzieva D. Combined use of mefformin and ethinyl estradiol - cyproterone acetate in polycystic ovary syndrome [J]. Eur J Obstet Gynecol Reprod Biol,2005,118(2) :209 -213.
  • 7Oalle F,Azziz R.Insulin resistance,polycystic ovary syndrome,and type 2 diabetes mellitus.Fertil Steril,2002,77(6):1095-1105.
  • 8The Rotterdann ESHRE/ASRM-sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome.Fertil Steril,2004,81(1):19-25.
  • 9Renato P,Alessandra G.Insulin-sensitizing agents in polycystic ovary syndrome.Eur J Endocrinol,2006,154(6):763-775.
  • 10Falsetti L,GamberaA.Tisi G.Efficiacy d the combination ethlnyl oestradiol and cyproterone acetate on endocrine,clinical and ultrasonographic profile in polycystic ovarian syndrome.Hum Reprod,2001,16(1):36-42.

共引文献105

同被引文献82

引证文献10

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部